Polymorphic CYP2C19 and N-acetylation:: human variability in kinetics and pathway-related uncertainty factors

被引:36
作者
Dorne, JLCM [1 ]
Walton, K [1 ]
Renwick, AG [1 ]
机构
[1] Univ Southampton, Clin Pharmacol Grp, Southampton SO16 7PX, Hants, England
关键词
human variability; pharmacokinetics; CYP2C19; N-acetylation; uncertainty factors; risk assessment; sensitive subgroups;
D O I
10.1016/S0278-6915(02)00210-7
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
CYP2C19-mediated oxidation and N-acetylation constitute major phase I and phase II polymorphic pathways of xenobiotic metabolism in humans. Analysis of human variability in kinetics for these pathways has been carried out for compounds metabolised extensively (>60%) by these routes. Data for minor substrates for CYP2C19 metabolism (10-60%) have also been analysed. Published pharmacokinetic studies (after oral and intravenous dosing) in CYP2C19 non-phenotyped healthy adults (NPs), and phenotyped extensive (EMs), slow-extensive (SEMs) and poor metabolisers (PMs) have been analysed using data for parameters that relate primarily to chronic exposure (metabolic and total clearances, area under the plasma concentration-time curve) and primarily to acute exposure (peak concentration). Similar analyses were performed for the N-acetylation pathway using data for fast acetylators (FA) and slow acetylators (SA). Interindividual variability in the kinetics of CYP2C19 substrates after oral dosage was greater in EMs than in NPs (60 vs 43% for clearances and 54 vs 45% for Cmax). Lower variability was found for N-acetylation for both phenotypes (32 and 22% for FA and SA, respectively). The internal dose of CYP2C19 substrates in PM subjects would be 3 1 fold higher than in EMs, while for N-acetylated substrates there was a three-fold difference between SA and FA subjects. Pathway-related uncertainty factors were above the default safety factor of 3.16 for most subgroups and values of 52 and 5.2 would be necessary to cover to the 99(th) centile of the poor metaboliser phenotype for CYP2C19 and N-acetylation, respectively. An exponential relationship (R-2=0.86) was found between the extent of CYP2C19 metabolism and the difference in internal dose between EMs and PMs. The kinetic default factor (3.16) would cover PMs for substrates for which CYP2C19 was responsible for up to 20-30% of the metabolism in EMs. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:225 / 245
页数:21
相关论文
共 83 条
  • [1] Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6
    Adedoyin, A
    Arns, PA
    Richards, WO
    Wilkinson, GR
    Branch, RA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) : 8 - 17
  • [2] ADEDOYIN A, 1994, PHARMACOGENETICS, V4, P27
  • [3] ADVENIER C, 1981, REV FR MAL RESPIR, V9, P365
  • [4] PHARMACOKINETICS OF ISONIAZID IN THE ELDERLY
    ADVENIER, C
    SAINTAUBIN, A
    GOBERT, C
    HOUIN, G
    ALBENGRES, E
    TILLEMENT, JP
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 10 (02) : 167 - 169
  • [5] Aitchison J., 1966, The Lognormal Distribution: With Special Reference to Its Uses in Economics
  • [6] EFFECT OF OMEPRAZOLE TREATMENT ON DIAZEPAM PLASMA-LEVELS IN SLOW VERSUS NORMAL RAPID METABOLIZERS OF OMEPRAZOLE
    ANDERSSON, T
    CEDERBERG, C
    EDVARDSSON, G
    HEGGELUND, A
    LUNDBORG, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (01) : 79 - 85
  • [7] POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS
    ANDERSSON, T
    REGARDH, CG
    LOU, YC
    ZHANG, Y
    DAHL, ML
    BERTILSSON, L
    [J]. PHARMACOGENETICS, 1992, 2 (01): : 25 - 31
  • [8] DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) : 131 - 137
  • [9] Pharmacokinetics and effect an caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole
    Andersson, T
    Holmberg, J
    Röhss, K
    Walan, A
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (04) : 369 - 375
  • [10] PHARMACOKINETICS OF [C-14] OMEPRAZOLE IN PATIENTS WITH LIVER-CIRRHOSIS
    ANDERSSON, T
    OLSSON, R
    REGARDH, CG
    SKANBERG, I
    [J]. CLINICAL PHARMACOKINETICS, 1993, 24 (01) : 71 - 78